Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction (NCT06362395)
🩺 Plain-English Summary (8th-Grade Level)
This international multi-centre phase 3 randomized control trial investigates whether giving a very high dose of radiation in a single treatment session (ultra-high dose: experimental) using advanced technology called MR-Linac is more effective than a high dose (control) for treating liver tumors that have spread from other parts of the body (liver metastases). This study also aims to identify predictors of treatment response and side effects by analyzing various factors such as imaging markers and genetic profiles. Liver metastases are common in several cancers, but surgery is often not feasible for many patients. Stereotactic body radiotherapy (SBRT), which delivers focused radiation to tumors, is an alternative treatment option. Previous studies have shown promising results with SBRT, but the optimal radiation dose for liver metastases is still uncertain. This study will look at patients with specific types of primary cancers known to respond well to SBRT. Treatment effectiveness will be assessed by monitoring tumor control, overall survival, and quality of life. By comparing ultra-high dose SBRT with standard high dose, the study aims to determine if the former can provide better tumor control with fewer side effects. If successful, this approach could offer a significant advancement in the treatment of liver metastases, potentially improving outcomes and quality of life for patients.
Who can join: Review the eligibility criteria below.
Location: Princess Margaret Cancer Centre — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT) (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Princess Margaret Cancer Centre — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 946-2360
Email: ali.hosni.abdalaty@uhn.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Liver Metastases
- End Hole vs. Pressure-Modulated Delivery of Y-90 Resin Microspheres to Liver Metastases. — Palo Alto, California
- Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment — New York, New York
- Proton Therapy in the Treatment of Liver Metastases — Loma Linda, California
- Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases — Montreal, Quebec
- OAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases — Madison, Wisconsin
- ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases — Houston, Texas
Explore by condition: All Liver Metastases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.